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Objective. In disease-modifying antirheumatic drug–
naive patients with early rheumatoid arthritis (RA) who
had achieved sustained low disease activity (a Disease Activ-
ity Score in 28 joints using the erythrocyte sedimentation
rate of £3.2 at both week 40 and week 52) after 1 year of
treatment with certolizumab pegol (CZP) at a standard
dose (200 mg every 2 weeks plus optimized methotrexate
[MTX]), we evaluated whether continuation of CZP treat-
ment at a standard dose or at a reduced frequency (200 mg
every 4 weeks plus MTX) was superior to stopping CZP
(placebo plus MTX) in maintaining low disease activity for
1 additional year.
Methods. A total of 293 patients from period 1 of
our study were re-randomized 2:3:2 in period 2 to CZP at
a standard dose (n5 84), CZP at a reduced frequency
(n5 127), or placebo plus MTX (CZP stopped) (n5 82).
The primary end point was the percentage of patients who
maintained low disease activity throughout weeks 52–104
without flares. We used a hierarchical testing scheme,
comparing CZP at a standard dose with CZP stopped. If P
< 0.05 was achieved, then CZP at a reduced frequency was
compared with CZP stopped (nonresponder imputation).
ClinicalTrials.gov identifier: NCT01521923.
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Results. The 293 patients from period 1 represen-
ted 36% fewer patients than projected, yielding a smaller
number of patients eligible for period 2. Higher propor-
tions of patients treated with the standard and reduced
frequency regimens maintained low disease activity than
those who had stopped CZP (48.8% and 53.2%, respec-
tively, versus 39.2% [P5 0.112 and P5 0.041, respectively;
nominal P value, first hierarchical test not significant]).
Similar trends were observed for radiographic non-
progression (change from baseline of £0.5 in modified
Sharp/van der Heijde score; 79.2% and 77.9% of patients,
respectively, versus 70.3%) and normative physical func-
tion (Health Assessment Questionnaire disability index
score of £0.5; 71.4% and 70.6% of patients, respectively,
versus 57.0%). Safety profiles were similar between all
groups, with no new safety signals identified for continu-
ing CZP to week 104. No deaths were reported.
Conclusion. The study failed to meet its primary
end point. However, there were no clinically meaningful
differences between the standard and reduced frequency
doses of CZP plus MTX; both controlled RA more effec-
tively than stopping CZP.
With the current armamentarium of treatments for
rheumatoid arthritis (RA), targeting achievement of low
disease activity or disease remission is recommended and
achievable in many patients. While there is agreement that
the clinical response induced by biologic disease-modifying
antirheumatic drugs (DMARDs) should ideally be
sustained, there is currently no consensus regarding the
length of time that defines a sustained response. Based on a
state of enduring disease control, clinicians must also con-
sider the possibility of successfully withdrawing or tapering
therapy (i.e., decreasing dose or dosing frequency), a treat-
ment concept referred to as the “induction-maintenance”
approach.
Tapering therapies after achieving a desired treat-
ment target has therefore become a topic of considerable
interest; results of several recent trials have suggested that
this may indeed be possible with several biologic agents,
with some of these trials also focusing on patients with
newly diagnosed RA (1). Applying such treatment strate-
gies may confer significant benefits to individual patients
through the reduction of medication dosage and the asso-
ciated risks while maintaining a state of disease control, as
well as through easing of the economic burden of the
disease as a result of increased cost effectiveness of the
treatment (2–5). Current recommendations issued by the
American College of Rheumatology (ACR) and the Euro-
pean League Against Rheumatism (EULAR) (2,6) sug-
gest continuation of therapy with only conditional
recommendations for tapering, thereby implying that RA
patients will thus spend long periods taking biologic
agents.
The aim of the C-EARLY study was to advance
potential care options with regard to the induction-
maintenance concept by evaluating the early initiation of
certolizumab pegol (CZP) in combination with optimized
methotrexate (MTX), as well as subsequent continua-
tion, tapering, or withdrawal of CZP, in a population of
DMARD-naive patients with early RA at high risk of pro-
gressive disease. CZP is an Fc-free, PEGylated, anti–tumor
necrosis factor (anti-TNF) biologic DMARD used to treat
both established and early RA in combination with MTX
(7–9). Period 1 of the C-EARLY study (NCT01519791)
assessed the efficacy and safety of 1 year of CZP in combi-
nation with optimized MTX versus optimized MTX alone.
Results from period 1 (9) showed that significantly higher
proportions of patients treated with CZP plus MTX
achieved clinical treatment targets such as sustained remis-
sion (28.9% had a Disease Activity Score in 28 joints [10]
using the erythrocyte sedimentation rate [DAS28-ESR] of
,2.6 at both week 40 and week 52; odds ratio [OR] 2.3
[95% confidence interval {95% CI} 1.50–3.47], P, 0.001)
and sustained low disease activity (43.8% had a DAS28-
ESR of #3.2 at both week 40 and week 52; OR 2.0 [95%
CI 1.38–2.78], P, 0.001) than did their counterparts
treated with placebo plus optimized MTX (15.0% had
sustained remission and 28.6% had sustained low disease
activity). There was also significant inhibition of the pro-
gression of articular structural damage and marked
improvements in the physical function of the CZP-treated
patients in comparison with the patients treated with opti-
mized MTX alone (9).
Period 2 of the C-EARLY study (NCT01521923)
was a continuation of period 1 for those patients who had
achieved sustained low disease activity at both week 40 and
week 52. We hypothesized that continuing the standard
dose of CZP or reducing dosage frequency would be supe-
rior to withdrawal of CZP treatment in maintaining clinical
response over an additional 52 weeks.
PATIENTS AND METHODS
Full details of patient eligibility and inclusion/exclusion
criteria for the C-EARLY period 1 study (NCT01519791) have
been reported previously (9). Briefly, eligible patients for the C-
EARLY period 1 study had active RA according to the 2010
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ACR/EULAR classification criteria (11), were DMARD-naive
with early disease (diagnosis ,1 year prior to randomization,
with 76% of patients randomized within 4 months of their diag-
nosis), and had poor prognostic factors for severe disease pro-
gression (positive at screening for rheumatoid factor or anti–
citrullinated protein antibody). Use of intraarticular, intramuscu-
lar, or intravenous corticosteroids at any dose was prohibited in
the C-EARLY study. Patients who had used intraarticular cor-
ticosteroids within 28 days of baseline (in C-EARLY period 1)
were excluded from study enrollment. The maximum allowed
dose of oral corticosteroids during the study was #10 mg/day
prednisone or equivalent, with changes in dose allowed only
between weeks 4 and 14 and between weeks 24 and 34 in period
1 of the study. Therefore, patients taking oral corticosteroids
were to maintain their dosage during period 2.
Patients in C-EARLY period 1 who had achieved
sustained low disease activity at weeks 40 and 52 (a key secondary
end point of period 1) after 52 weeks of CZP plus optimized
MTX treatment were eligible for enrollment into C-EARLY
period 2. Sustained low disease activity was chosen as the entry
criterion for period 2 as a clinically relevant criterion that can be
used to identify patients who are proven responders to treatment.
Study design. C-EARLY period 2 was a phase III, mul-
ticenter, double-blind, placebo-controlled, randomized study con-
ducted in Europe, Australia, North America, and Latin America
at 103 participating sites (of the 181 that participated in C-
EARLY period 1) from February 2013 to July 2015. Eligible
patients from period 1 treated with 200 mg CZP every 2 weeks
plus MTX were re-randomized at week 52 at a ratio of 2:3:2 to
receive the standard CZP dose of 200 mg every 2 weeks plus
MTX (CZP standard group), the reduced frequency regimen of
200 mg CZP every 4 weeks plus MTX (reduced frequency group),
or CZP stopped (placebo every 2 weeks plus MTX) (CZP stopped
group) (Figure 1). Re-randomization at week 52 was performed
centrally using an Interactive Voice/Web Response System
(IXRS) and stratified by time since RA diagnosis at baseline (#4
months or .4 months) and week 52 sustained remission status.
Week 0 (period 1) was considered the study baseline. Placebo
plus MTX–treated patients from period 1 who had sustained low
disease activity at both week 40 and week 52 entered period 2 as a
separate group (“MTX responder” group), continued to receive
placebo plus MTX only, and were not re-randomized. These
patients were analyzed post hoc as a descriptive arm only.
The primary efficacy end point was the proportion of
patients with sustained low disease activity (DAS28-ESR of #3.2
at both week 40 and week 52) who maintained low disease activity
(DAS28-ESR of #3.2) for all 5 consecutive study visits to week
104 without flares. The key secondary end point was the propor-
tion of patients with sustained remission (DAS28-ESR of,2.6 at
both week 40 and week 52) who maintained remission (DAS28-
Figure 1. C-EARLY study design, showing set of enrolled patients. a 5 optimized methotrexate (MTX), defined as dose titrated from 10 mg/
week (week 0) and increasing by 5 mg every 2 weeks (Q2W) to a maximum dose of 25 mg/week by weeks 6–8. Patients unable to tolerate
$15 mg/week by week 8 were withdrawn from the study. b 5 low disease activity (LDA), defined as a Disease Activity Score in 28 joints using
the erythrocyte sedimentation rate (DAS28-ESR) of #3.2. Low disease activity was considered to be maintained if continued throughout weeks
52–104 without disease flares. Patients reporting a flare had to meet the following 3 criteria at 2 consecutive visits 2 weeks apart: 1) an increase
in the DAS28-ESR of $0.6 above the DAS28-ESR at week 52; 2) a DAS28-ESR of .3.2; and 3) in the investigator’s judgment, an increase
in the patient’s rheumatoid arthritis (RA) activity. Sustained remission was defined as a DAS28-ESR of ,2.6 at both week 40 and week 52.
c 5 randomization stratified by time since RA diagnosis at baseline (#4 months or .4 months). d 5 randomization stratified by time since RA
diagnosis at baseline and by sustained remission status at week 52. CZP5 certolizumab pegol; LD5 loading dose; DMARD5disease-modifying
antirheumatic drug; PBO5 placebo; Q4W5 every 4 weeks. See Patients and Methods for descriptions of groups.
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ESR of ,2.6) for all 5 consecutive study visits to week 104 with-
out flares. Additional secondary end points included the overall
proportions of patients with low disease activity (DAS28-ESR of
#3.2), remission (DAS28-ESR of ,2.6), and normative physical
function (defined as a Health Assessment Questionnaire disabil-
ity index [HAQ DI] score [12] of#0.5), as well as the proportion
of patients achieving radiographic nonprogression during period
2 (defined as a change in the modified Sharp/van der Heijde
score [SHS] [13] of#0.5 from week 52 to week 104) and over the
2 years of the study (defined as a change from baseline in the
SHS of#0.5 at week 104).
Time to flare was also explored as a secondary end point.
An exploratory end point was the proportion of patients with dis-
ease flares who underwent reinduction with CZP treatment and
subsequently re-achieved low disease activity. In this study, dis-
ease flares had to be self-reported by the patient at a study visit;
solicitation by the study investigators was not mandated by the
protocol. In addition, patients reporting a flare also had to meet
the following 3 criteria at 2 consecutive visits 2 weeks apart: 1) an
increase in the DAS28-ESR of $0.6 above the DAS28-ESR at
week 52; 2) a DAS28-ESR of .3.2; and 3) in the investigator’s
judgment, an increase in the patient’s RA activity. In the event of
a confirmed disease flare, patients received a loading dose of
CZP (400 mg at 3 subsequent visits) followed by the standard
dose (200 mg every 2 weeks) until the end of the study. Patients
who experienced flares twice or who did not re-achieve low dis-
ease activity within 12 weeks after reintroduction of CZP were
withdrawn from the study.
Study drug. Placebo was supplied as 0.9% saline, and
CZP was supplied as a 200 mg solution. Both were in prefilled
syringes for subcutaneous injection and were administered up to
week 102. Additional details regarding the initiating CZP dose
have been described previously (9).
Oral MTX was dose-optimized throughout the study.
MTX was initiated during period 1 (9) at 10 mg/week and esca-
lated by 5 mg every 2 weeks to a maximum of 25 mg/week (with a
minimum of 15 mg/week) by week 8, if tolerated. This maximum
tolerated (“optimized”) dose was maintained and continued to
be administered every week from week 52 to week 103.
Study procedures and evaluations. In period 2,
patients were assessed every 8–12 weeks at weeks 52, 64, 76, 84,
92, and 104. All study personnel were blinded with regard to
treatment, except for a separate group who supervised and
administered the study medication and determined ESR but who
otherwise had no involvement in the study. Safety analyses
included all treatment-emergent adverse events (AEs), seri-
ous AEs (SAEs), and severe treatment-emergent AEs, as well
as clinical laboratory measurements.
Ethical approval. This study was conducted in accor-
dance with the current version of the applicable regulatory and
International Conference on Harmonisation Guidelines for
Good Clinical Practice, the ethical principles that have their ori-
gin in the principles of the Declaration of Helsinki, and the local
laws of the countries involved.
Statistical analysis. Based on a priori assumptions of
response during period 1, 455 CZP-treated patients from period
1 were expected to be eligible for period 2, with 130, 195, and 130
patients randomly assigned to the CZP standard, reduced fre-
quency, and CZP stopped groups, respectively. Given this sample
size, power was calculated to be 99% and 92% to detect a statisti-
cally significant difference in maintaining low disease activity
between the CZP standard and reduced frequency groups,
respectively, compared with the CZP stopped group at a given
a5 0.05. Response rates of 95%, 90%, and 75% were assumed
for the CZP standard, reduced frequency, and CZP stopped
groups, respectively.
Statistical testing for the primary and key secondary end
points was performed in a hierarchical manner. CZP standard
versus CZP stopped was tested first. If the difference was signifi-
cant at the a5 0.05 level, then reduced frequency versus CZP
stopped was tested. The full analysis set (those with sustained low
disease activity at both week 40 and week 52 [per the IXRS] with
valid post–week 52 efficacy measurements for DAS28-ESR) was
used for all efficacy data except for radiographic data, which used
the radiographic data set (those with valid radiographs at base-
line, week 52, and week 104/withdrawal visit). Where reported in
radiographic analyses, the MTX responder patients treated with
placebo plus MTX throughout the study fulfilled the same crite-
ria for the radiographic data set. The safety set comprised all
patients who received at least 1 dose of study medication, and
was used for the safety data.
A logistic regression model with factors for treatment,
region, time since RA diagnosis at baseline, and week 52
sustained remission status was used for the primary and key sec-
ondary end points, as well as for the proportions of patients
achieving low disease activity, remission, normative physical func-
tion, and radiographic nonprogression during period 2. The
Clopper-Pearson method was used to generate 95% CIs for the
logistic regression models.
Missing data from patients who entered period 2 but
withdrew before the end of the study were imputed using nonre-
sponder imputation for the primary and key secondary end
points. Radiographic analyses used linear extrapolation. In post
hoc analyses, last observation carried forward (LOCF) imputa-
tion was used for the proportions of patients achieving low dis-
ease activity, remission, and normative physical function.
RESULTS
Patient disposition and baseline characteris-
tics. A total of 293 CZP-treated patients from period 1
were re-randomized at week 52 and enrolled in this study,
with 84 patients in the CZP standard group, 127 patients
in the reduced frequency group, and 82 patients in the
CZP stopped group. These patients represent 44% of the
660 CZP-treated patients in period 1. However, this was
36% fewer than the planned randomizations of 130, 195,
and 130 patients, respectively, due to fewer patients than
projected with sustained low disease activity at the end of
period 1. Of those who were re-randomized, 84, 126, and
79 patients comprised the full analysis set; 72, 113, and 75
patients comprised the radiographic set (see Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40196/abstract).
In period 2, 14 of 84 patients (16.7%) in the CZP
standard group, 15 of 127 patients (11.8%) in the reduced
frequency group, 10 of 82 patients (12.2%) in the CZP
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stopped group, and 7 of 66 MTX responder patients
(10.6%) discontinued treatment by week 104. The most
common reason for discontinuation was treatment-
emergent AEs, in 4 of 84 patients (4.8%), 8 of 127 patients
(6.3%), 7 of 82 patients (8.5%), and 2 of 66 patients
(3.0%), respectively (see Supplementary Figure 1, http://
onlinelibrary.wiley.com/doi/10.1002/art.40196/abstract).
Patient demographic characteristics were generally well
balanced across all treatment groups (Table 1) except for
sex, with a higher percentage of women in the CZP stan-
dard group (66 of 84 [78.6%]) than in the reduced fre-
quency group (86 of 126 [68.3%]) and CZP stopped group
(58 of 79 [73.4%]). Disease characteristics at both baseline
and week 52 (Table 1; also see Supplementary Table 1,
http://onlinelibrary.wiley.com/doi/10.1002/art.40196/abstract)
were also reasonably well balanced across all groups.
The mean weekly optimized MTX dose was similar across
all groups (mean 20–22 mg/week), with a maximum of
25 mg/week.
Efficacy. At week 104, 41 of 84 patients (48.8%)
in the CZP standard group and 67 of 126 patients
(53.2%) in the reduced frequency group had maintained
low disease activity without flares, compared with 31
of 79 patients (39.2%) in the CZP stopped group (P5
0.112 and P5 0.041, respectively; nominal P value due
to lack of significance in first hierarchical test). Of
patients with sustained remission, 22 of 50 (44.0%) in
the CZP standard group and 36 of 83 (43.4%) in the
reduced frequency group maintained remission to week
104 without flares, compared with 17 of 51 patients
Figure 2. Clinical response in period 2 of the C-EARLY study, showing the full analysis set. A, Proportion of patients in whom low disease
activity (LDA) was maintained, and proportion in whom remission (REM) was maintained, at week 104. Odds ratios (ORs) with 95% confi-
dence intervals (95% CIs) and corresponding P values are from a logistic regression model with factors for treatment, region, time since
rheumatoid arthritis (RA) diagnosis, and sustained remission status at week 52. Only patients with disease in sustained remission at week 52
were included in the analysis for maintained remission at week 104. Nonresponder imputation was used for missing data. B, Proportion of
patients with low disease activity, defined as a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) of
#3.2. C, Proportion of patients with disease in remission, defined as a DAS28-ESR of ,2.6. D, Proportion of patients with normative physi-
cal function, defined as a Health Assessment Questionnaire disability index score of #0.5. B–D show results of post hoc analyses. The last
observation carried forward approach was used to impute missing data. CZP5 certolizumab pegol. See Patients and Methods for descriptions
of groups.
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(33.3%) in the CZP stopped group (P5 0.274 and
P5 0.253, respectively) (Figure 2A).
Despite the failure to achieve the primary end
point, the overall data demonstrate that patients continu-
ing CZP at either the standard or reduced frequency doses
were better able to maintain clinical response compared
with those who stopped CZP, as illustrated by low disease
activity, remission, and normative physical function. In
post hoc analyses using LOCF imputation, higher propor-
tions of patients in the CZP standard and reduced fre-
quency groups achieved low disease activity (66 of 84
[78.6%] and 103 of 126 [81.7%], respectively), remission
(53 of 84 [63.1%] and 90 of 126 [71.4%], respectively), and
normative physical function (60 of 84 [71.4%] and 89 of
126 [70.6%], respectively) at week 104 compared with
those who stopped CZP (50 of 78 [64.1%; 1 patient’s data
missing] achieved low disease activity, 37 of 78 [47.4%; 1
patient’s data missing] achieved remission, and 45 of 79
[57.0%] achieved normative physical function) (Figures
2B–D). Furthermore, mean DAS28-ESR and HAQ DI
score values were also numerically lower throughout period
2 for patients continuing CZP treatment compared with
those who stopped (see Supplementary Figure 2, http://
onlinelibrary.wiley.com/doi/10.1002/art.40196/abstract).
Few patients exhibited radiographic progression in
period 2 (change in SHS of .0.5 from week 52); these
included 7 of 72 patients (9.7%) in the CZP standard
group and 18 of 113 patients (15.9%) in the reduced fre-
quency group, compared with 14 of 74 patients (18.9%) in
the CZP stopped group. Over the 2 years of the study,
patients continuing CZP treatment (in the CZP standard
and reduced frequency groups) exhibited stabilization of
structural damage, with numerically fewer patients (15 of
72 [20.8%] and 25 of 113 [22.1%], respectively) experienc-
ing radiographic progression at week 104 (change in SHS
of .0.5 from baseline) in comparison with patients who
stopped CZP (22 of 74 [29.7%]) after week 52 (Figure 3).
Relatively few disease flares were recorded in
patients during this study, which was possibly due to the
limitation of the patients having to self-report flares to the
investigator. Patients self-reporting flares included 7 of 84
(8.3%) in the CZP standard group, 3 of 126 (2.4%) in the
reduced frequency group, and 10 of 79 (12.7%) in the
CZP stopped group. Most flares occurred in these patients
by week 64 (i.e., 12 weeks after the change in treatment
dosing) (Figure 4). Patients with flares underwent re-
induction with the standard dose of CZP (including a load-
ing dose), and 80% of them (16 of 20; 7 in the CZP
standard group, 1 in the reduced frequency group, and 8 in
the CZP stopped group) subsequently achieved low dis-
ease activity again within 12 weeks.
MTX responders. Compared with the 44% of
patients (293 of 660) in whom CZP treatment was initi-
ated, a smaller proportion of patients who were only
started on optimized MTX achieved sustained low disease
activity at both week 40 and week 52 and continued to
period 2, representing 30% (66 of 219) of the patients
Figure 3. Radiographic progression in the C-EARLY study.
Shown is the radiographic data set with methotrexate (MTX)
responder patients meeting the same criteria (those who had valid
radiographs at baseline, week 52, and week 104/withdrawal visit).
A, Radiographic progression and nonprogression rates. B, Cumula-
tive probability of change in modified Sharp/van der Heijde score
(SHS) from week 52 to week 104. C, Cumulative probability of
change in SHS from baseline to week 104. Results for MTX
responder patients were obtained using post hoc analyses. Radio-
graphic nonprogression was defined as a change in the SHS of
#0.5 from baseline or week 52. Radiographic progression was
defined as a change in the SHS of .0.5 from baseline or week 52.
One outlier in the certolizumab pegol (CZP) stopped group was
excluded. Linear extrapolation was used for missing data. Symbols
in B and C represent values for each patient. See Patients and
Methods for descriptions of groups.
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treated with placebo plus MTX. Sixty patients were
included in the radiographic analyses as a separate group.
The safety set included 83 patients in the CZP standard
group, 127 in the reduced frequency group, 81 in the CZP
stopped group, and 66 MTX responder patients.
In this group of patients with an enhanced
response to MTX therapy, exploratory, descriptive post
hoc analyses were performed with LOCF imputation. At
week 104, 81.3% (52 of 64; 2 patients’ data missing),
59.4% (38 of 64; 2 patients’ data missing), and 59.4% (38
of 64; 2 patients’ data missing) of these patients had
achieved good clinical response—low disease activity,
remission, and normative physical function, respectively
(see Supplementary Figure 3, http://onlinelibrary.wile
y.com/doi/10.1002/art.40196/abstract). However, a higher
proportion of MTX responders experienced radio-
graphic progression over the 2 years of the study (41.7%
[25 of 60]) compared with the 3 groups initially treated
with CZP (Figure 3).
Safety. The incidence of treatment-emergent AEs
in period 2 was similar across all 3 re-randomized groups:
63.9% of patients (53 of 83) in the CZP standard group,
63.8% (81 of 127) in the reduced frequency group, and
59.3% (48 of 81) in the CZP stopped group experienced
treatment-emergent AEs, with a lower rate observed in
the MTX responder group (50.0% [33 of 66]). Infections
were the most frequent treatment-emergent AEs, with a
higher proportion of patients continuing CZP treatment
reporting infections (31.3% [26 of 83] in the CZP standard
group and 38.6% [49 of 127] in the reduced frequency
group), compared with 27.2% (22 of 81) of those who
stopped CZP and 15.2% (10 of 66) of MTX responders.
Serious infections and infestations were experienced by
1.2% of patients (1 of 83) in the CZP standard group,
0.8% (1 of 127) in the reduced frequency group, 2.5% (2
of 81) in the CZP stopped group, and 1.5% (1 of 66) of
MTX responders. For patients exposed to CZP treatment
at any time in period 2 (patients in the CZP standard and
reduced frequency groups and any patients who received
CZP after disease flares), the incidence rate of infections
was 45.1 per 100 patient-years. The rate of SAEs was simi-
lar between all groups (4.8% of patients [4 of 83] in the
CZP standard group, 7.1% [9 of 127] in the reduced fre-
quency group, 7.4% [6 of 81] in the CZP stopped group,
and 6.1% [4 of 66] of MTX responders).
There were higher rates of drug-related treatment-
emergent AEs in the CZP-treated patients: 30.1% of
patients (25 of 83) in the CZP standard group and 23.6%
(30 of 127) in the reduced frequency group, compared
with 17.3% (14 of 81) in the CZP stopped group and
15.2% (10 of 66) of MTX responders. Discontinuations
due to treatment-emergent AEs followed a similar pattern,
being observed in 2.4% of patients (2 of 83) in the CZP
standard group and 5.5% (7 of 127) in the reduced fre-
quency group, compared with 4.9% (4 of 81) in the CZP
stopped group and 1.5% (1 of 66) of MTX responders.
Figure 4. Kaplan-Meier plot of time to rheumatoid arthritis (RA) disease flare, showing the full analysis set. Disease flares had to be self-
reported by the patient to the investigator at a study visit; solicitation by the study investigators was not mandated by the protocol. Patients
reporting a flare had to meet the following 3 criteria at 2 consecutive visits 2 weeks apart: 1) an increase in the Disease Activity Score in 28
joints using the erythrocyte sedimentation rate (DAS28-ESR) of $0.6 above the DAS28-ESR at week 52; 2) a DAS28-ESR of .3.2; and 3) in
the investigator’s judgment, an increase in the patient’s RA activity. Time to flare was defined as the time from the date of the week 52 injection
of study medication to the date of the first flare visit for a confirmed flare. Patients who did not have a flare were censored at the date of the
latest assessment of the DAS28-ESR. CZP5 certolizumab pegol. See Patients and Methods for descriptions of groups.
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Continuing treatment at the standard dose was not
associated with an increased risk of malignancies com-
pared with that in the reduced frequency or CZP stopped
groups. The overall incidence of malignant tumors was
low, with 2.4% of patients (3 of 127) in the reduced fre-
quency group (1 with breast cancer, 1 with lip squamous
cell carcinoma, and 1 with myxoid liposarcoma) and 2.5%
of patients (2 of 81) in the CZP stopped group (both with
prostate cancer) reporting any malignant tumors. No
patients developed malignancies in the CZP standard or
MTX responder groups (Table 2), nor were there any
reports of hematologic reactions or demyelinating
disorders. No deaths were reported in the re-randomized
treatment groups. There was 1 death due to cardiac failure
in the MTX responder group 11 days after the final dose
of study medication. The event was not considered to be
related to study medication. The safety profile of MTX
responder patients was comparable to that of the patients
who were re-randomized.
DISCUSSION
C-EARLY is the first reported randomized,
double-blind study with an anti-TNF biologic DMARD
that compares the following 3 treatment strategies: contin-
uation at full dose, tapering, or withdrawal of biologic ther-
apy, in combination with optimized MTX, in maintaining
low disease activity after 1 year of anti-TNF treatment in
DMARD-naive patients with early and progressive, active
RA. Previous studies, such as the Productivity and Remis-
sion in a Randomized Controlled Trial of Etanercept vs.
Standard of Care in Early Rheumatoid Arthritis (PRIZE)
study (14), compared the effect of tapering to a half dose
(25 mg/week) of etanercept in combination with MTX
with the effects of etanercept withdrawal (with MTX) and
treatment with placebo alone. The Optimal Protocol for
Methotrexate and Adalimumab Combination Therapy in
Early Rheumatoid Arthritis (OPTIMA) study (15) com-
pared the effect of continuing the full dose of adalimumab
with the effects of biologic therapy withdrawal (with
MTX) and MTX monotherapy.
The primary end point of the present study was not
achieved. Fewer patients than projected from period 1
were eligible to enter period 2 (i.e., achieved sustained low
disease activity), which may have resulted in an underpow-
ered study. The use of sustained low disease activity at 2
consecutive study visits (both week 40 and week 52) as the
entry criterion for period 2 was more difficult to achieve
Table 2. Summary of AEs*
CZP standard
dose (n5 83),
no. (%)
CZP reduced
frequency
(n5 127),
no. (%)
CZP stopped
(n5 81),
no. (%)
MTX responders
(n5 66),
no. (%)
CZP at
any time (n5 223),
no. (%)/
event rate†
Any treatment-emergent AEs ($5% in any
system organ class)
53 (63.9) 81 (63.8) 48 (59.3) 33 (50.0) 145 (65.0)/163.5
Gastrointestinal disorders 5 (6.0) 6 (4.7) 8 (9.9) 7 (10.6) 13 (5.8)/6.9
General disorders and administration site conditions 4 (4.8) 10 (7.9) 4 (4.9) 5 (7.6) 16 (7.2)/6.9
Infections and infestations 26 (31.3) 49 (38.6) 22 (27.2) 10 (15.2) 82 (36.8)/57.8
Injury, poisoning, and procedural complications 5 (6.0) 14 (11.0) 7 (8.6) 1 (1.5) 20 (9.0)/9.0
Investigations 11 (13.3) 12 (9.4) 8 (9.9) 8 (12.1) 23 (10.3)/13.3
Metabolism and nutrition disorders 3 (3.6) 14 (11.0) 6 (7.4) 5 (7.6) 17 (7.6)/9.0
Musculoskeletal and connective tissue disorders 8 (9.6) 12 (9.4) 12 (14.8) 6 (9.1) 23 (10.3)/12.0
Nervous system disorders 6 (7.2) 7 (5.5) 1 (1.2) 1 (1.5) 15 (6.7)/14.1
Renal and urinary disorders 5 (6.0) 2 (1.6) 0 1 (1.5) 8 (3.6)/3.9
Respiratory, thoracic, and mediastinal disorders 5 (6.0) 8 (6.3) 3 (3.7) 1 (1.5) 13 (5.8)/6.9
Skin and subcutaneous tissue disorders 8 (9.6) 9 (7.1) 3 (3.7) 2 (3.0) 17 (7.6)/8.6
Any malignant tumor 0 3 (2.4) 2 (2.5) 0 4 (1.8)/1.7
Serious treatment-emergent AEs 4 (4.8) 9 (7.1) 6 (7.4) 4 (6.1) 16 (7.2)/6.9
Serious infections and infestations 1 (1.2) 1 (0.8) 2 (2.5) 1 (1.5) 2 (0.9)/0.9
Discontinuation due to treatment-emergent AEs 2 (2.4) 7 (5.5) 4 (4.9) 1 (1.5) 10 (4.5)/NA
Treatment-emergent AEs requiring MTX reduction 0 5 (3.9) 1 (1.2) 1 (1.5) NA
Drug-related treatment-emergent AEs 25 (30.1) 30 (23.6) 14 (17.3) 10 (15.2) 60 (26.9)/NA
Severe treatment-emergent AEs 1 (1.2) 4 (3.1) 2 (2.5) 3 (4.5) 5 (2.2)/NA
Deaths (treatment-emergent AEs leading to death) 0 0 0 1 (1.5) 0
* Safety set, comprising all patients who received at least 1 dose of study medication. Terms are from Medical Dictionary for Regulatory Activi-
ties, version 17.0. NA5 not available.
† Includes adverse events (AEs) occurring in period 2 in any group after receiving certolizumab pegol (CZP) in period 2, including treatment-
emergent AEs occurring after induction/reinduction with CZP for patients in the methotrexate (MTX) responder and CZP stopped groups. The
total number of patients exposed to CZP in period 2 was used as the denominator; event rates are per 100 patient-years.
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than a single-visit criterion. The primary end point of
period 2 was stringent, as patients were required to have
maintained low disease activity throughout the entirety of
the second year for 5 consecutive visits rather than just at a
single study visit. The expected 20% and 15% differences
between the CZP standard and reduced frequency groups
versus the CZP stopped group in the maintenance of low
disease activity to week 104 were also not realized. It
should be noted that the study protocol design was under-
taken in 2010, prior to the issuance of the 2011 ACR/
EULAR guidelines (16), in which the Simplified Disease
Activity Index (17) and Boolean-based definitions of low
disease activity and remission superseded DAS28-ESR–
based definitions as the closest reflection of “deep” disease
control.
Nevertheless, results from period 2 of C-EARLY
may still be of value to rheumatologists and patients, and
could inform care options, since the data suggest that after
1 year of CZP treatment at the standard dose (200 mg
every 2 weeks plus MTX), continuing treatment for an
additional year at a reduced frequency dosage (200 mg
every 4 weeks plus MTX) provided control of disease activ-
ity comparable to continuing treatment at the standard
dose. A numerically higher proportion of patients continu-
ing CZP at both dosages maintained clinical response and
improvements in physical function in comparison with
patients who stopped CZP treatment after 1 year.
Unexpectedly, a slightly higher proportion of
patients continuing treatment at the reduced frequency
dose achieved low disease activity, remission, and norma-
tive physical function compared with patients continuing a
standard dose of CZP. This could have been due to the
smaller-than-expected sample size, which led to more vari-
ability in the results. However, the numerical differences
between the CZP standard dose and reduced frequency
groups are small and not considered clinically meaningful.
Treatment of patients very early in the course of
RA is associated with inhibition of the progression of joint
damage as well as with better clinical outcomes. The 52-
week data from C-EARLY period 1 revealed that early
initiation of CZP plus MTX significantly inhibited joint
destruction compared with no CZP treatment (9). The
results of exploratory analyses from period 2 suggest that
early initiation of CZP treatment can provide better and
continued protection against progression of structural
damage over a 2-year period, regardless of whether CZP
was continued after 1 year. This difference was larger
when compared with the descriptive arm of the MTX
responders, even though those patients had a good clinical
response with 2 years of therapy with optimized MTX
alone. We note that our study was not powered to detect
differences in radiographic progression rates; however, our
findings are consistent with previous data from Japanese
MTX-naive patients with early RA in the Certolizumab-
Optimal Prevention of joint damage for Early RA (C-
OPERA) trial, in which patients who had been treated
with CZP plus MTX for 1 year exhibited lower rates
of radiographic progression for 1 additional year after
stopping CZP, in comparison with patients who had
been receiving 2 years of MTX monotherapy (7,18).
Similar results were also reported in DMARD-naive
patients started on adalimumab plus MTX in the High
Induction Therapy with Anti-Rheumatic Drugs (HIT
HARD) study (19), although with a shorter (24-week)
treatment duration.
In addition to the clinical efficacy described above,
early initiation of CZP plus MTX has demonstrated
benefits over optimized MTX alone in patient-reported
measures such as workplace and household productivity
(20). More patients who continued the standard or
reduced frequency doses were able to maintain the initial
52-week improvements up to week 104 in comparison with
patients who stopped CZP (21).
MTX therapy in this study was optimized by week
8 (i.e., patients were given the maximum tolerated dose,
between 15 mg and 25 mg) (9). To our knowledge, the
Dutch U-Act-Early study (22) and our international C-
EARLY study are the only trials to mandate per-protocol
optimization of MTX to achieve high levels of MTX dos-
age in DMARD- and MTX-naive patients with early RA.
This optimization may in part explain the good clinical
responses achieved by the MTX responders over the
course of the 2 years.
There were low numbers of flares reported in this
study, a limitation which was likely due to the requirement
that flares be self-reported by the patient. The physicians
involved in this study did not have a systematic evaluation
method and were not mandated to formally assess disease
flares. Although DAS components were measured at each
study visit, the investigator remained blinded with regard
to the DAS score. The low number of flares is not reflected
by the relatively high proportion of patients (;50%) who
did not maintain low disease activity. Of those who had dis-
ease flares, most (80%) achieved low disease activity again,
and no safety issues were identified in those patients. How-
ever, because too few patients were identified as having a
disease flare, no formal conclusions can be drawn about
the safety and efficacy of reintroduction of the CZP stan-
dard dose in restoring low disease activity. Further evalua-
tion of flares among the patients in this study is warranted.
No new safety signals were identified for an additional 52
weeks of CZP plus MTX treatment, and the safety profile
was consistent between all groups, including the MTX
responder patients, who had been treated with placebo
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plus optimized MTX for 2 years and had never received
CZP.
Overall, the data from the first 52 weeks of the C-
EARLY study demonstrated a favorable benefit-to-risk
ratio for early initiation of CZP plus MTX therapy in
DMARD-naive patients within 1 year of receiving their
diagnosis of active RA with poor prognostic factors for dis-
ease progression (9). Clinical improvements achieved by
the early initiation of CZP therapy during period 1 of the
study were maintained in numerically more patients who
continued at the standard or reduced frequency doses,
thus providing support for the “induction-maintenance”
approach for this specific population of patients with early
RA who had never been exposed to either synthetic or bio-
logic DMARDs. Exploratory analyses of radiographic data
reported from period 2 suggested that early CZP initiation
could be a better option for avoiding structural damage in
this patient population compared with treatment with
MTX alone, supporting the results reported from other
studies (18). Further research would be needed to identify
the characteristics of patients who would be able to stop
CZP therapy successfully. By investigating the effect of
continuing or tapering biologic DMARD therapy after
reaching a disease target, our study contributes to the
body of knowledge supporting the induction-maintenance
treatment approach, and our results inform the evolving
paradigms of disease management in RA while also
highlighting the need for further clinical trial evidence.
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